tiprankstipranks
Trending News
More News >
Research Frontiers Inc. (REFR)
NASDAQ:REFR
US Market

Research Frontiers (REFR) AI Stock Analysis

Compare
145 Followers

Top Page

REFR

Research Frontiers

(NASDAQ:REFR)

Select Model
Select Model
Select Model
Neutral 44 (OpenAI - 5.2)
Rating:44Neutral
Price Target:
$0.78
▼(-38.90% Downside)
Action:ReiteratedDate:03/21/26
The score is held down primarily by weak financial performance (negative and worsening operating cash flow, fragile profitability quality, and higher leverage) and a bearish technical setup (below key moving averages with negative MACD). The earnings call provides a modest offset due to improved balance-sheet position and a broader commercial pipeline, but near-term revenue and collections remain uncertain and valuation support is limited due to losses.
Positive Factors
Diversified OEM Pipeline
A broader, multi-OEM pipeline reduces single-customer concentration and raises the probability of multi-program royalty streams as projects move into production. Over a 2–6 month horizon, validated OEM launches and high-volume quotations materially increase the chance of sustained royalty revenue once integration timelines complete.
Product and Technical Advances
Technical progress (neutral/black aesthetics, IR/UV variants, yield gains) addresses OEM selection criteria and reduces per-unit costs. These enduring R&D advances strengthen competitive differentiation and lower barriers to adoption, improving long-term margins and making SPD more attractive across automotive and architectural markets.
Improved Balance Sheet Flexibility
Transitioning to a debt-free position and adding dedicated capital increases financial optionality for commercialization and supports working-capital needs during OEM ramp cycles. Over the medium term this reduces refinancing risk and gives management flexibility to support licensee transitions and commercialization investments.
Negative Factors
Persistent Negative Cash Flow
Sustained negative operating cash flow indicates the business cannot self-fund commercialization and remains dependent on external funding or equity dilution. If OEM royalties do not materialize on schedule, continued cash burn could force recurring financing, diluting shareholders and constraining long-term execution.
Elevated Historical Leverage and Balance-Sheet Risk
A prior sharp increase in leverage reduced balance-sheet flexibility and raised refinancing and dilution risk. Even with recent corrective steps, the historical erosion of equity and reliance on external capital highlight vulnerability to funding shocks or delayed royalty receipts as programs transition into production.
Volatile Revenue and Weak Profitability
Inconsistent top-line trends and negligible gross profit point to fragile earnings quality and limited operating leverage. Because Research Frontiers earns royalties tied to partner commercialization, sustained revenue growth depends on partner execution; prolonged volatility impairs cash generation and long-term profitability.

Research Frontiers (REFR) vs. SPDR S&P 500 ETF (SPY)

Research Frontiers Business Overview & Revenue Model

Company DescriptionResearch Frontiers Incorporated develops and markets technology and devices to control the flow of light worldwide. The company develops and licenses suspended particle device (SPD-Smart) light-control technology to companies that manufacture and market the SPD-Smart chemical emulsion, light-control film made from the chemical emulsion, the light-control panels made by laminating the film, and electronics to power end-products incorporating the film, as well as lamination services for and the end-products, such as windows, skylights, and sunroofs. Its SPD-Smart light-control technology is used in various product applications, including windows, sunshades, skylights, and interior partitions for homes and buildings; automotive windows, sunroofs, sun-visors, sunshades, rear-view mirrors, instrument panels, and navigation systems; aircraft windows; museum display panels, and eyewear products; and flat panel displays for electronic products. The company serves architectural, automotive, marine, and aerospace and appliance applications. Research Frontiers Incorporated was incorporated in 1965 and is headquartered in Woodbury, New York.
How the Company Makes MoneyResearch Frontiers makes money primarily by licensing its SPD-SmartGlass intellectual property to third parties and earning royalties tied to commercial sales of SPD-enabled products. Under its model, the company licenses the right to use its patents, know-how, and trademarks to a network of partners that may include film manufacturers (who produce the SPD light-control film), glass and glazing companies (who laminate the film into finished glass/plastic panels), and OEMs or integrators (who incorporate finished panels into vehicles, buildings, or other products). Revenue is therefore largely driven by royalty income based on the volume and value of SPD products sold into end markets (notably automotive and architectural). In addition to recurring royalties, the company may also receive other licensing-related payments (e.g., license fees or similar contractual payments) when entering into or maintaining licensing arrangements; if specific terms or amounts are not publicly available for a given agreement, null. The company’s earnings are significantly influenced by the pace of adoption of SPD smart glass by OEM programs (especially automotive model launches), the production volumes achieved by its manufacturing partners, and the commercialization success of products that incorporate SPD technology.

Research Frontiers Earnings Call Summary

Earnings Call Date:Mar 05, 2026
(Q4-2025)
|
% Change Since: |
Next Earnings Date:Apr 30, 2026
Earnings Call Sentiment Positive
The call communicated a constructive operational and commercial outlook: management highlighted expanded OEM engagements (including Cadillac, Ferrari, McLaren), a broader automotive pipeline with four high-volume quotations, launch of an architectural retrofit product, technical progress on Black SPD, and a strengthened, debt-free balance sheet supported by a targeted $1.1M private placement. Offsetting these positives were near-term headwinds tied to Gauzy's French rehabilitation and related liquidity reallocation that slowed collections, royalty impacts from licensee bankruptcies (six-figure effect), geopolitical disruptions affecting logistics, and the inherent timing lag between automotive integration and royalty revenues. On balance, the strategic progress and diversification of programs and markets outweigh the short-term payment and timing risks, though investors should expect revenue realization to follow program production ramps rather than immediately.
Q4-2025 Updates
Positive Updates
Debt-Free Balance Sheet and Fresh Capital
Company entered 2026 debt-free, strengthened working capital, and completed an oversubscribed $1.1 million private placement at $1 per share (with 5-year warrants); participants included long-term shareholders and the owner of an SPD licensee involved in architectural retrofit.
Automotive Production Continuity and Supply-Chain Resilience
Maintained production continuity through license transitions (e.g., Ferrari transitioned from AGP/Soliver to Isoclima), with Isoclima sales exceeding minimum annual royalty thresholds in Q3 and Q4 2025; demonstrated ability to shift suppliers to preserve series production.
Broader and Deeper Automotive Pipeline
SPD validated across 4 OEMs and 4 models in production; company reported 4 high-volume quotations and additional specialty programs with potential annual volumes in the tens of thousands, creating the broadest automotive pipeline in company history.
Major OEM and Concept Vehicle Endorsements
Cadillac Celestiq (General Motors flagship) launched with 4-quadrant SPD smart roof—first major U.S. OEM adoption; Ferrari and McLaren in production; Mercedes showcased SPD across ~75% of vehicle glazing in a concept vehicle, signaling broader OEM interest.
Architectural Retrofit Product Launch
Launched SPD retrofit architectural product with licensee AIT/LTI at GlassBuild America; identified four initial retrofit projects across commercial, residential and historic retrofit use-cases that enable interior installation without facade removal, expanding addressable market substantially.
Product and Technical Advances
Progress on Black SPD (neutral/black aesthetic preferred by OEMs), new SPD film variants, optical refinements, IR/UV integration, improved manufacturing yields and ancillary systems development aimed at enabling broader adoption.
Long-Term Investment in Platform
Company has invested over $125 million in SPD and related markets to date, providing a substantial infrastructure and technology foundation that management views as a driver of durable future growth.
Operational Continuity Outside France
SPD emulsion production in Israel and SPD film production in Germany continue despite Gauzy's French rehabilitation process, supporting ongoing program execution.
Negative Updates
Gauzy French Rehabilitation and Liquidity Reallocation
Gauzy's French subsidiaries entered a court-supervised rehabilitation process that reallocated liquidity to satisfy monitors, temporarily reducing access to funds for other parts of Gauzy and slowing payments to Research Frontiers; approximately half of Research Frontiers' receivables from Gauzy are subject to the French process.
Royalty Impact from Licensee Bankruptcies
Bankruptcies of license suppliers AGP and Soliver produced a recorded royalty impact in 2025 described as a six-figure reduction; these supply disruptions required multiple transitions to maintain production continuity.
Receivables and Collection Delays
Collections were slower in 2025 due to Gauzy-related disruptions and the French monitoring process; management indicated receivable approvals through the French monitor could take 1–2 weeks per submission and noted ongoing collections but with short-term delays.
Geopolitical and Operational Disruptions
Regional conflict affected Gauzy personnel and logistics (Israeli airspace closures), delaying some technical meetings and complicating movement of emulsion/product between Israel and Germany; management noted potential to shift more production to Germany to mitigate future disruptions.
Limited Size and Timing of Capital Raise Caused Concern
The $1.1M private placement was modest and selectively sourced (including family members of a director), prompting shareholder questions about timing given prior guidance that cash was sufficient for multiple years assuming normal collections; management said the raise was precautionary given unpaid receivables and strategic opportunities.
Near-Term Revenue Uncertainty and Timing Lag
Management emphasized that meaningful revenue growth from automotive programs will only occur as OEM programs move from quotation and integration into production; automotive adoption cycles are long and revenue lags technical/engineering milestones, so near-term revenue remains uncertain.
Investor Concerns About Gauzy Stability and Funding
Uncertainty remains around Gauzy's broader funding (a proposed $50M funding plan had not been finalized publicly) and Gauzy's stock trading under $1 raised concerns about its NASDAQ status and potential customer hesitancy, which could indirectly affect payment timing and program execution.
Company Guidance
Guidance from the call was that Research Frontiers entered 2026 debt‑free with strengthened working capital after completing an oversubscribed $1.1 million private placement at $1 per share (5‑year warrants at escalating strike prices; shares subject to ≥6‑month hold), and management said royalties improved when adjusted for one‑time licensee events despite a six‑figure hit in 2025 from AGP/Soliver bankruptcies; Ferrari production was successfully transitioned to Isoclima (exceeding minimum annual royalty thresholds in Q3 and Q4 2025), Gauzy’s French subsidiaries entered court‑supervised rehabilitation in mid‑November (Nov. 13) while SPD emulsion production in Israel and film production in Germany continue, and Gauzy backlog was described in the “tens of millions”; commercial momentum includes production with Ferrari, McLaren and Cadillac (Celestiq), a Mercedes concept covering ~75% glazing, four high‑volume automotive quotations plus specialty programs with potential annual volumes in the “tens of thousands,” launch of four initial architectural retrofit projects, continued R&D (Black SPD, IR/UV variants, yield improvements) and the company noted over $125 million historically invested in SPD—management reiterated that revenue should follow as programs move from quotation to production and pointed to cost reductions from scale and licensee investments.

Research Frontiers Financial Statement Overview

Summary
Fundamentals remain weak: volatile/declining revenue, minimal gross profit and only near-breakeven reported profitability, while operating cash flow and free cash flow are consistently negative and cash burn worsened in 2025. Balance-sheet risk is elevated due to the sharp increase in debt-to-equity as equity fell.
Income Statement
24
Negative
Revenue has been volatile and recently declined (2025 down ~9% vs. 2024), following uneven growth in prior years. Profitability remains weak: 2024 showed a steep net loss with deeply negative margins, while 2025 shows near-breakeven reported profitability but with essentially no gross profit and minimal EBITDA margin (~1%), suggesting limited operating leverage and fragile earnings quality. Overall, the income profile reflects inconsistent top-line momentum and an inability to produce sustainable profits.
Balance Sheet
38
Negative
Leverage has increased materially: debt-to-equity rose from ~0.50 (2024) to ~1.25 (2025) as equity fell sharply, reducing balance-sheet flexibility. Total debt is now larger than equity, elevating refinancing and dilution risk if losses or cash burn persist. A positive offset is that total assets still exceed total debt, but returns on equity have been poor historically (negative in prior years and not meaningfully positive in 2025).
Cash Flow
18
Very Negative
Cash generation is a clear weakness, with operating cash flow and free cash flow consistently negative across the period. 2025 operating cash flow worsened to about -$1.33M versus -$0.79M in 2024, indicating rising cash burn despite the appearance of improved earnings. Free cash flow improved versus 2024 on a growth basis, but it remains meaningfully negative, implying continued dependence on external funding.
BreakdownDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.12M1.34M909.60K539.69K1.26M
Gross Profit934.57K1.07M-1.45M539.69K1.26M
EBITDA-1.95M-1.18M-1.86M-2.45M-1.66M
Net Income-2.05M-1.31M-1.91M-2.67M-1.85M
Balance Sheet
Total Assets2.25M4.04M3.85M5.37M4.55M
Cash, Cash Equivalents and Short-Term Investments664.30K1.99M2.48M4.23M3.03M
Total Debt1.17M1.30M267.72K464.13K646.22K
Total Liabilities1.32M1.44M332.79K569.59K762.06K
Stockholders Equity933.63K2.60M3.52M4.80M3.78M
Cash Flow
Free Cash Flow-1.33M-790.44K-2.30M-2.18M-1.81M
Operating Cash Flow-1.33M-788.82K-2.30M-2.18M-1.80M
Investing Cash Flow-726.00-1.62K55.59K2.69M-2.78M
Financing Cash Flow0.00308.67K484.50K3.45M86.26K

Research Frontiers Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.27
Price Trends
50DMA
1.10
Negative
100DMA
1.36
Negative
200DMA
1.49
Negative
Market Momentum
MACD
-0.05
Positive
RSI
35.90
Neutral
STOCH
39.91
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For REFR, the sentiment is Negative. The current price of 1.27 is above the 20-day moving average (MA) of 0.99, above the 50-day MA of 1.10, and below the 200-day MA of 1.49, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 35.90 is Neutral, neither overbought nor oversold. The STOCH value of 39.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for REFR.

Research Frontiers Risk Analysis

Research Frontiers disclosed 14 risk factors in its most recent earnings report. Research Frontiers reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Research Frontiers Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
66
Neutral
$76.55M354.279.95%2.21%-15.60%
61
Neutral
$37.18B12.37-10.20%1.83%8.50%-7.62%
58
Neutral
$108.30M47.70-53.09%-15.76%-25.27%
52
Neutral
$24.34M3.4450.99%-48.54%
52
Neutral
$68.01M110.942.42%38.22%70.68%
44
Neutral
$30.04M-14.39-122.90%-16.49%-59.21%
* Technology Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
REFR
Research Frontiers
0.86
-0.30
-25.52%
MIND
MIND Technology
8.47
1.80
26.99%
NEON
Neonode
1.45
-7.30
-83.43%
CPSH
CPS Technologies
3.78
2.07
121.05%
ODYS
Odysightai
6.62
0.12
1.85%
HOLO
MicroCloud Hologram
2.02
-42.38
-95.45%

Research Frontiers Corporate Events

Private Placements and Financing
Research Frontiers Announces $1.1 Million Private Placement
Positive
Feb 18, 2026

On February 18, 2026, Research Frontiers entered into subscription agreements with private accredited investors, including family members of a company director and the owner of a licensee producing SPD-SmartGlass products, for a private placement of 1.1 million common shares at $1.00 per share, matching the February 13, 2026 closing price. The transaction provides the company with $1.1 million in proceeds and includes one warrant per share, exercisable at step-up prices between $1.10 and $1.50 through February 28, 2031, with all shares issued in the placement and upon future warrant exercise remaining unregistered and subject to at least a six-month holding period, which may affect liquidity considerations for participating investors.

The most recent analyst rating on (REFR) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on Research Frontiers stock, see the REFR Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Mar 21, 2026